This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teva (TEVA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin (AMRN) is scheduled to release third-quarter earnings on Nov 1.
Pfizer Succeeds in Pain Study, Forms JV to Make CNS Drugs
by Zacks Equity Research
Pfizer (PFE) and Lilly present detailed data from a phase III study on pain candidate, tanezumab. The former forms a new company for CNS treatment in alliance with Bain Capital.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $21.45 in the latest trading session, marking a +0.85% move from the prior day.
Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?
by Zacks Equity Research
Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.
Regeneron's Dupixent Meets Goals in Nasal Polyps Studies
by Zacks Equity Research
Regeneron's (REGN) atopic dermatitis drug, Dupixent meets goals in two late-stage studies for nasal polyps.
Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing
by Zacks Equity Research
Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.
Novartis Presents Data on Multiple Sclerosis Drug Gilenya
by Zacks Equity Research
Novartis (NVS) announces encouraging data from a late-stage trial, ASSESS, on multiple sclerosis drug, Gilenya, which further reinforces its efficacy in treating relapses.
Novartis' Applications for MS Drug Accepted by FDA & EMA
by Zacks Equity Research
Novartis (NVS) progresses with its MS candidate, siponimod, as both the FDA and the EMA accepts the applications for the drug.
Merck & Other Pharma Players Await FDA Decisions in October
by Kinjel Shah
FDA grants approval to 41 new treatments till the end of September.
Why Teva Pharmaceutical Industries Ltd. (TEVA) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality
by Zacks Equity Research
Eli Lilly's (LLY) CGRP antibody Emgality injection gains an FDA approval for the preventive treatment of migraine in adults.
Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead
by Ekta Bagri
Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.
Lilly's Migraine Drug Emgality Wins Positive CHMP Opinion
by Zacks Equity Research
Eli Lilly's (LLY) CGRP antibody Emgality gains a positive view from CHMP for the treatment of migraine in adults, who encounter minimum four migraine spells a month.
AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU
by Zacks Equity Research
The CHMP gives positive opinion for combination use of AbbVie's (ABBV) Venclexta and Roche's Rituxan for relapsed/refractory CLL in patients who have received at least one prior therapy.
AstraZeneca's Fasenra Long-Term Asthma Study Data Positive
by Zacks Equity Research
AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.
Regeneron Gains on Eylea, Dupixent and Pipeline Progress
by Zacks Equity Research
Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.
New Marijuana Stocks? & Earnings from ORCL and FDX | Free Lunch
by Ryan McQueeney
Ryan McQueeney touches on the trade war's latest tariff threats and a key FDA approval for Teva Pharmaceuticals. He also highlights two surprising companies which might have a chance to profit from the marijuana boom. Later, Ryan previews Oracle and FedEx's earnings reports.
Teva's (TEVA) Migraine Drug Ajovy Receives FDA Approval
by Zacks Equity Research
Teva Pharmaceutical's (TEVA) anti-CGRP drug, Ajovy, gets FDA nod as a preventive treatment of migraine in adult patients.
Allergan Frown Lines Study Passes Test on Higher Botox Dose
by Zacks Equity Research
Allergan (AGN) presents positive results from a study, evaluating a higher dose of Botox for the treatment of glabellar lines.
Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi present encouraging data from a late-stage trial on dermatitis drug Dupixent in adolescents.
Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija
by Zacks Equity Research
The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.
AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia
by Zacks Equity Research
AbbVie (ABBV) gets FDA approval to include MRD-negativity (undetectable disease) data from phase III MURANO study on the label of Venclexta.
Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down
by Zacks Equity Research
Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra
Lilly, Teva, Pfizer & Others Await FDA Decisions in September
by Kinjel Shah
FDA grants approval to 34 new treatments this year so far.